Screening for and validated quantification of amphetamines and of amphetamine‐ and piperazine‐derived designer drugs in human blood plasma by gas chromatography/mass spectrometry
Journal of Mass Spectrometry June 1, 2003 Frank T. Peters, Simone Schaëfer, Roland F. Staack et al. 171 citations
A method was developed to screen for and simultaneously quantify classical stimulants (amphetamine, methamphetamine, ethylamphetamine, MDA, MDMA, MDEA, BDB, MBDB) and newer designer drugs (4-methylthioamphetamine, p-methoxyamphetamine, p-methoxymethamphetamine, and several piperazine derivatives) along with two metabolites in human blood plasma. The technique uses gas chromatography/mass spectrometry with selected-ion monitoring after solid-phase extraction and derivatization. The method was linear from 5 to 1000 µg/L for all analytes, with a limit of quantification of 5 µg/L. Accuracy and precision met required limits except for MDBP. The assay was validated and applicable for confirming immunoassay results positive for amphetamines or ecstasy-type designer drugs.